Neurotrack Technologies, Inc.

Over the last three years, researchers have made significant progress in defining key drivers of Alzheimer’s disease, which affects more than 50 million people worldwide. Tests such as a PET scan, MRI

Neurotrack Technologies, Inc. adjusts its approach to promoting its digital screening tool intended to help diagnose and manage cognitive decline linked to aging following a competitor’s challenge in

Neurotrack Technologies Inc. 120 Hawthorne AvenuePalo Alto, CA 94301 E-mail: elli@neurotrack.com Web Site: www.neurotrack.com Contact: Elli Kaplan, CEO Industry Segment: Diagnostics

Device Transactions Medical device developers closed the third quarter of 2013 with $644 million in financing, a big decline compared with the previous two quarters, which each tallied both tallied ov